| Outcome Measures: |
Primary: Liver stiffness measurements (LSM) of subjects, As determined by magnetic resonance elastography (MRE), From enrollment to the treatment at 24 and 48 weeks | Secondary: Efficacy Evaluation of MASLD in fibrosis, This includes: 1. Difference from baseline in LSM of subjects based on FibroScan; 2. The proportion of LSM of subjects on MRE reduced by ≥15%; 3. The proportion of LSM of subjects on FibroScan reduced by ≥15%, From enrollment to the treatment at 24 and 48 weeks|Efficacy Evaluation of MASLD in liver fatty quantification, This includes: 1. Difference from baseline in liver fatty quantification of subjects based on magnetic resonance imaging proton density fat fraction(MRI-PDFF); 2. Difference from baseline in liver fatty quantification of subjects based on FibroScan; 3. The proportion of liver fatty quantification of subjects based on MRI-PDFF was reduced by ≥30%; 4. The proportion of liver fatty quantification of subjects based on FibroScan was reduced by ≥30%;, From enrollment to the treatment at 24 and 48 weeks|Efficacy Evaluation of MASLD in non-invasive biological indicators related to liver fibrosis, This includes:1.NAFLD fibrosis score(NFS) = - 1.675 + \[0.037 ×Age\] + \[0.094 × body mass index(BMI) (kg/m2)\] + \[1.13 × fasting plasma glucose(FPG)/ Diabetes (Yes=1，No= 0)\] + \[0.99 × aspartate aminotransferase(AST)/alanine aminotransferase(ALT)\] - \[0.013 × platelet count(PLT) (×109/L)\] - \[0.66 × Albumin(ALB) (g/dL)\]; NFS \<-1.455, -1.455-0.675, and \>0.675 mean expressed as low, medium, and high risk, respectively(39); 2.Fibrosis-4(FIB-4) index= \[Age× AST (U/L)\]/\[PLT (×109/L)× ALT (U/L)1/2\];, From enrollment to the treatment at 24 and 48 weeks|Renal function, This includes:This includes:Difference from baseline in renal function related parameters of subjects, primarily including uric acid(UA), urea nitrogen(BUN), creatinine(Cr), urine albumin-to-creatinine ratio(UACR)., From enrollment to the treatment at 24 and 48 weeks|Liver function, This includes:Difference from baseline in liver function related parameters of subjects, primarily including AST, ALT, gamma-glutamyl transferase(GGT), alkaline phosphatase(ALP), ALB, total bilirubin(TBiL)., From enrollment to the treatment at 24 and 48 weeks|Lipid metabolism, This includes:Difference from baseline in lipid metabolism related parameters of subjects, primarily including Triglyceride(TG), total cholesterol(TC), low-density lipoprotein cholesterol(LDL-C), high-density lipoprotein cholesterol(HDL-C)., From enrollment to the treatment at 24 and 48 weeks|Efficacy Evaluation of T2DM, FPG, From enrollment to the treatment at 24 and 48 weeks|Efficacy Evaluation of T2DM, fasting insulin concentrations(FINS), From enrollment to the treatment at 24 and 48 weeks|Efficacy Evaluation of T2DM, fasting C-peptide(FCP), From enrollment to the treatment at 24 and 48 weeks|Efficacy Evaluation of T2DM, hemoglobin A1c(HbA1c), From enrollment to the treatment at 24 and 48 weeks|Efficacy Evaluation of T2DM, homeostatic model assessment of insulin resistance(HOMA-IR), From enrollment to the treatment at 24 and 48 weeks
|
